DexCom Receives New Coverage from Analysts at JPMorgan Chase & Co. (DXCM)
Stock analysts at JPMorgan Chase & Co. started coverage on shares of DexCom (NYSE:DXCM) in a report issued on Friday, American Banking and Market News reports. The firm set an “overweight” rating and a $32.00 price target on the stock. JPMorgan Chase & Co.’s price target indicates a potential upside of 16.32% from the company’s current price.
Several other analysts have also recently commented on the stock. Analysts at Wedbush raised their price target on shares of DexCom (NYSE:DXCM) from $18.00 to $31.00 in a research note to investors on Tuesday, August 13th. They now have an “outperform” rating on the stock. Separately, analysts at Feltl & Co. raised their price target on shares of DexCom (NYSE:DXCM) from $16.50 to $18.25 in a research note to investors on Monday, August 12th. They now have a “sell” rating on the stock. Finally, analysts at Jefferies Group raised their price target on shares of DexCom (NYSE:DXCM) from $21.00 to $27.00 in a research note to investors on Thursday, August 8th. They now have a “buy” rating on the stock.
Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and five have issued a buy rating to the company. The stock has a consensus rating of “Hold” and an average target price of $24.03.
Shares of DexCom (NYSE:DXCM) traded down 0.62% during mid-day trading on Friday, hitting $27.34. The stock had a trading volume of 556,622 shares. DexCom has a 52-week low of $12.03 and a 52-week high of $28.48. The stock has a 50-day moving average of $25.69 and a 200-day moving average of $20.69. The company’s market cap is $1.951 billion.
DexCom, Inc is a medical device company. The Company focuses on the design, development and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes, and for use by healthcare providers in the hospital for the treatment of both diabetic and non-diabetic patients.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.